Evercore Trust Company N.a. Lowers stake in Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX) : Evercore Trust Company N.a. reduced its stake in Boston Scientific Corporation by 1.71% during the most recent quarter end. The investment management company now holds a total of 12,352,333 shares of Boston Scientific Corporation which is valued at $295,097,235 after selling 214,949 shares in Boston Scientific Corporation , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Boston Scientific Corporation makes up approximately 0.93% of Evercore Trust Company N.a.’s portfolio.

Other Hedge Funds, Including , Ameritas Investment Partners boosted its stake in BSX in the latest quarter, The investment management firm added 1,724 additional shares and now holds a total of 26,825 shares of Boston Scientific Corporation which is valued at $640,849. Boston Scientific Corporation makes up approx 0.04% of Ameritas Investment Partners’s portfolio.Glenmede Trust Co Na boosted its stake in BSX in the latest quarter, The investment management firm added 3,898 additional shares and now holds a total of 45,720 shares of Boston Scientific Corporation which is valued at $1,103,681. Boston Scientific Corporation makes up approx 0.01% of Glenmede Trust Co Na’s portfolio.Mutual Of America Capital Management boosted its stake in BSX in the latest quarter, The investment management firm added 15,558 additional shares and now holds a total of 227,731 shares of Boston Scientific Corporation which is valued at $5,429,107. Boston Scientific Corporation makes up approx 0.11% of Mutual Of America Capital Management’s portfolio.Msi Financial Services Inc boosted its stake in BSX in the latest quarter, The investment management firm added 1,580 additional shares and now holds a total of 4,186 shares of Boston Scientific Corporation which is valued at $99,041.

Boston Scientific Corporation opened for trading at $23.92 and hit $24.18 on the upside on Friday, eventually ending the session at $24.17, with a gain of 0.88% or 0.21 points. The heightened volatility saw the trading volume jump to 47,12,158 shares. Company has a market cap of $32,889 M.

On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .Company shares were Reiterated by The Benchmark Company on Jul 28, 2016 to “Buy”, Firm has raised the Price Target to $ 31 from a previous price target of $25 .

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.